Read by QxMD icon Read

Journal of Population Therapeutics and Clinical Pharmacology

Thao Huynh, Patricia Lecca, Martine Montigny, Roxanne Gagnon, Mark Jeffrey Eisenberg, Claude Lauzon, Samer Mansour, Stephane Rinfret, Marc Afilalo, Michel Nguyen, Simon Kouz, Jean-Pierre Dery, Richard Harvey, Erick Schampaert, Jean-Claude Tardif
  Background          Adherence to statins is often sub-optimal and declines over time. Direct costs incurred by patients are frequently cited as responsible for inadequate statin adherence. To determine whether survivors of ST-segment elevation myocardial infarction (STEMI), who benefit from low or no cost drug dispensation, have optimal long-term adherence to statins, we aimed to evaluate the ten-year adherence to statin of these patients. Methods          The AMI-QUEBEC Study follows a cohort of STEMI survivors hospitalized at 17 hospitals in Quebec, Canada during the year 2003...
November 6, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Scott Bryant
Abstracts from the CAPT / ACTP Annual Meeting 2018.
October 29, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Joel Lexchin
Invited Editorial.
September 24, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Nigel Rawson, Arpit Chhabra
BACKGROUND: A Canadian Agency for Drugs and Technologies in Health (CADTH) therapeutic review concluded that bevacizumab and ranibizumab have similar efficacy and safety in treating retinal conditions and recommended bevacizumab be used as preferred initial therapy based on a cost-saving perspective. Such use would be off-label because bevacizumab is not approved for these conditions and has a serious safety warning (SSW) in its Product Monograph (PM) about intravitreal use. OBJECTIVE: To evaluate whether the Ontario Public Drug Programs (OPDP) reimbursement is provided only for off-label use for serious, life-threatening or severely debilitating conditions and not when the drug's PM contains a SSW against such use...
September 20, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Angela Rocchi, Fergal Mills
BACKGROUND: The pan-Canadian Pharmaceutical Alliance (pCPA) was established in 2010 to negotiate confidential prices for drugs coming forward from Canada's centralized health technology assessment (HTA) agency reviews, on behalf of the participating public drug plans. OBJECTIVE:  To analyze the activities of the pCPA, to determine: alignment of HTA agency recommendations and pCPA negotiation decisions; the role of health economics in pCPA activities; and patterns of implicit prioritization...
August 7, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Shaik Afshan Jabeen, Padmaja Gaddamanugu, Ajith Cherian, Kandadai Mridula Mridula, Dasari Uday Kumar, Angamuttu Kanikannan Meena
Objectives To study the clinical profile and outcome in patients with epilepsy who developed psychogenic non-epileptic seizures (PNES) associated with levetiracetam (LEV) use.   Methods In this prospective observational study, conducted over 1 year, 13 patients with epilepsy and PNES, documented by video electroencephalogram (VEEG) while on LEV, were included. Those with past history of psychiatric illnesses were excluded. VEEG, high-resolution magnetic resonance imaging, neuropsychological and psychiatric evaluation were performed...
July 11, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Kamelia Mirdamadi, Tim Salinas, Reza Vali, Manny Papadimitropoulos, Micheline Piquette-Miller
Pregnancy Outcomes after Exposure to TNF-α Inhibitors During Pregnancy for the Treatment of Arthritic Diseases: A Meta-Analysis   Authors: Mirdamadi K, Salinas T, Vali R, Papadimitripulous M, Piquette-Miller M Background: Auto-immune arthritic diseases affect many women of child-bearing age. Tumor necrosis factor (TNF)-α inhibitors are currently used for the treatment of various immune-mediated diseases during pregnancy. However, there has been no evaluation of safety in the treatment of arthritic diseases during gestation...
April 10, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Maxim Eskin, Dean T Eurich, Scot H Simpson
BACKGROUND - A variety of methods are used to define exposure in pharmacoepidemiologic studies. Although each method has known biases, the relative effect of these biases on an observed association has not been fully examined. OBJECTIVE - To explore the influence of different exposure definitions on estimates, using the association between metformin and all-cause mortality as a proto-typical model. METHODS - New users of oral anti-hyperglycemic drugs were identified using administrative health databases from Alberta, Canada between 1998 and 2010...
March 20, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Bernadette Safe, Annette Joosten, Roslyn Giglia
METHODS: A systematic review of current evidence using various electronic databases was conducted. Studies were appraised using a recognised clinical appraisal tool. RESULTS: Seven studies published between 1998 and 2014 met the inclusion criteria. There is some evidence that difficulties with fine motor skills, visual motor integration, and balance skills persist in people who have been prenatally exposed to alcohol. Most studies did not focus on adolescent or adult participants in isolation, making it difficult to generalise results...
March 1, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Jiayu Liu, SherWin Wong, Gary Foster, Anne Holbrook
Introduction Evidence suggests that newly licensed physicians are not adequately prepared to prescribe safely. There is currently no national pre-licensure prescribing competency assessment required in North America. This study's purpose was to survey Canadian medical school leaders for their interest in and perceived need for a nationwide prescribing assessment for final year medical students.   Method In spring of 2015, surveys were disseminated online to medical education leaders in all 17 Canadian medical schools...
February 2, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Shenzhen Yao, Lisa Lix, Yvonne Shevchuk, Gary Teare, David F Blackburn
BACKGROUND: In 2007, a drug benefit plan for Seniors (SDP) was launched in Saskatchewan, Canada. SDP capped out-of-pocket costs at $15 per prescription for individuals aged 65 and older. OBJECTIVES: To quantify the impact of the SDP on chronic medication adherence.  Methods: A retrospective cohort study was conducted for participants aged 65 or older who were eligible to the SPD, controlled by a younger group aged 40 to 64 who were ineligible. Adherence was measured over 365 days using medication possession ratio (MPR)...
January 15, 2018: Journal of Population Therapeutics and Clinical Pharmacology
Olufinsho Awodele, Samson Fatoki
BACKGROUND: Nigeria has been plagued by counterfeit and poor quality medicines with several studies indicating varying degree of prevalence. Thus, this study is aimed at determining the anticounterfeiting strategies employed by local drug manufacturers in Lagos-Nigeria. METHOD: The first phase was a descriptive study which involves the use of a self-administered closed ended structured questionnaire to assess the anticounterfeiting strategies employed by local manufacturers in Nigeria...
December 4, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Nigel Rawson
A publicly-funded pharmacare program (OHIP+) was announced in the 2017 Ontario budget for all children and young adults that will begin in January 2018 and cover drugs in the Ontario Public Drug Programs (OPDP) formulary. In this commentary, drugs indicated for rare disorders commonly occurring in childhood that were reviewed by the Common Drug Review (CDR) between 2004 and 2016 are examined to assess the Ontario reimbursement situation. OPDP reimburse few of these drugs and only about half of those covered are accessible with consistency and without onerous conditions...
December 1, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Dean Trevor Eurich, Karly A Achtymichuk, Jeffrey A Johnson, Jashu K Minhas-Sandhu, Mu Lin
BACKGROUND: Objectives: To develop a healthy user index to serve as a method of confounding adjustment in future observational studies of preventive therapies. METHODS: A large administrative database of patients with type 2 diabetes was split in half randomly, yielding derivation and validation cohorts. Influenza vaccination was used as a 'prototypical marker' of a healthy user. In our derivation cohort, we fitted a mixed effects logistic regression model, and a points-based system was used to construct the index...
November 22, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Elena R Lungu, Orlando J Manti, Mitchell A H Levine, Douglas A Clark, Tanya M Potashnik, Carol I McKinley
BACKGROUND: Prescription drug expenditures represent a significant component of health care costs in Canada, with estimates of $28.8 billion spent in 2014. Identifying the major cost drivers and the effect they have on prescription drug expenditures allows policy makers and researchers to interpret current cost pressures and anticipate future expenditure levels. OBJECTIVES: To identify the major drivers of prescription drug costs and to develop a methodology to disaggregate the impact of each of the individual drivers...
September 1, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Lawrence B Gutman, Ben J Wilson
Midodrine is an oral, peripherally acting alpha-adrenergic agonist. After gaining Food and Drug Administration (FDA) approval in 1996 for orthostatic hypotension, its use has evolved to target vasoplegic conditions such as intradialytic hypotension in the end-stage renal disease population, refractory ascites in cirrhotic patients to support diuresis, and in hepatorenal syndrome. Upon oral ingestion, the drug undergoes enzymatic hydrolysis to an active metabolite, desglymidodrine. Its use has been well tolerated at 2...
August 23, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Céline Thibault, Nastya Kassir, Yves Théorêt, France Varin, Catherine Litalien, Julie Autmizguine
BACKGROUND: Extended piperacillin-tazobactam (TZP) infusions have been associated with favourable outcomes. There are currently no pediatric dosing recommendations. OBJECTIVES: To determine appropriate TZP dosing strategies in children 2 months - 6 years according to age and different minimal inhibitory concentrations (MICs). METHODS: Age and weight were simulated for 1000 children. Post-hoc pharmacokinetic parameter estimates were generated using published clearance and volume of distribution data...
August 21, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Caroline Croteau, Laurent Mottron, Nancy Presse, Jean-Eric Tarride, Marc Dorais, Sylvie Perreault
BACKGROUND: Psychoactive medications are commonly prescribed to autistic individuals, but little is known about how their use changes after diagnosis. OBJECTIVES: This study describes the use of psychoactive drugs in children and young adults newly diagnosed with autism spectrum, between the year before and up to 5 years after diagnosis. METHODS: Multivariable logistic regression was used to examine the relationship between the use psychoactive drugs before the first diagnosis of autism spectrum condition (from 1998 to 2010), and the clinical and demographic characteristics, identified from public health care databases in Quebec...
August 18, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Ana Hanlon-Dearman, Sayma Malik, Julia Wellwood, Karen Johnston, Holly Gammon, Kathy N Andrew, Breann Maxwell, Sally Longstaffe
BACKGROUND: Research suggests that prenatal alcohol exposure (PAE) and Fetal Alcohol Spectrum Disorder (FASD) increases the risk of insecure caregiver-child attachment and related negative child emotional-behavioural outcomes. Research also shows positive effects of attachment-focused interventions in preventing disrupted caregiver-child attachment relationships; however, such interventions have not been specifically adapted for children with FASD. OBJECTIVES: This paper describes the implementation, challenges, and results of a community home-based attachment intervention, Circle of Security® (COS), with preschool children affected by PAE/FASD in Manitoba, Canada...
June 14, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Jessica J Jalbert, Michel Rossignol, Bernard Astruc, Franck Baylé, Clementine Nordon, Bernard Avouac, Frédéric Rouillon, Lucien Abenhaim, Lamiae Grimaldi-Bensouda
BACKGROUND: Long-acting injectable (LAI) atypical antipsychotics are associated with improved adherence and reduced relapse rates in schizophrenia but reminder-based interventions may further improve outcomes. OBJECTIVES: To assess an institutional medication adherence program's (IMAP) effectiveness on adherence and psychiatric hospitalizations among schizophrenia patients taking risperidone LAI (RLAI). METHODS: Between 2009 and 2010, we recruited patients meeting DSM-IV criteria for schizophrenia treated with RLAI receiving outpatient care from psychiatric centres in France...
May 30, 2017: Journal of Population Therapeutics and Clinical Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"